Aurinia Pharmaceuticals is a commercial stage biopharmaceutical company focused on developing therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company recently received FDA approval for their first commercially available drug product. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub in Rockville, Maryland, and focuses its development efforts globally. Please visit https://lupkynispro.com to learn more about our product.